Karan J. Yagnik

Dr. Karan J. Yagnik

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
CGChristopher S Graffeo
Christopher S Graffeo
KYKaran J. Yagnik
Karan J. Yagnik
LCLucas P. Carlstrom
Lucas P. Carlstrom
NLNikita Lakomkin
Nikita Lakomkin
IBIrina Bancos
Irina Bancos
JGJamie J Van Gompel
Jamie J Van Gompel

14 October 2021 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
KYKaran J. Yagnik
Karan J. Yagnik
AGAnshit Goyal
Anshit Goyal
JGJamie J Van Gompel
Jamie J Van Gompel

27 September 2021 in Pituitary
Verified
Journal Article
Closed access
PDF file
KYKaran J. Yagnik
Karan J. Yagnik
DEDana Erickson
Dana Erickson
IBIrina Bancos
Irina Bancos
JAJohn L. D. Atkinson
John L. D. Atkinson
GCGarret Choby
Garret Choby
JGJamie J Van Gompel
Jamie J Van Gompel

24 October 2025 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
HBHareesha Rishab Bharadwaj
Hareesha Rishab Bharadwaj
DDDushyant Singh Dahiya
Dushyant Singh Dahiya
PDPriyal Dalal
Priyal Dalal
MFMuhtasim Fuad
Muhtasim Fuad
HRHafiz Ali Raza
Hafiz Ali Raza
HAHassam Ali
Hassam Ali
Background: Artificial intelligence (AI), which includes machine learning and deep learning, is fundamentally changing public health in gastroenterology and hepatology—fields grappling with a significant global disease burden. Objective: This review focuses on the population-level applications and impact of AI, highlighting its role in shifting healthcare strategies from reactive treatment to proactive prevention. Results: AI demonstrates substantial improvements across many different areas. In colorectal cancer, AI models significantly boost detection rates, successfully identifying a large majority of high-risk individuals often missed by traditional screening methods. For metabolic dysfunction-associated steatotic liver disease (MASLD), advanced non-invasive tests offer a high degree of reliability in detecting liver fibrosis. The identification of viral hepatitis is enhanced with excellent accuracy, and gastrointestinal infection surveillance benefits from wastewater analysis that provides an early warning system weeks ahead of clinical case reporting. Furthermore, AI improves the diagnosis of upper GI cancers, such as gastric cancer, with higher diagnostic capability, and facilitates precision public health in inflammatory bowel disease (IBD) through highly accurate risk prediction models. Challenges: Despite these important advances, significant hurdles remain. Key challenges include ensuring diverse and representative data to prevent algorithmic bias, protecting patient privacy, establishing robust regulatory frameworks for new technologies, and successfully moving innovations from research settings into practical, real-world deployment. Conclusion: The unequal distribution of AI development and access between high-income countries and low- and middle-income countries risks exacerbating existing health disparities. To fully realize AI's transformative potential for global public health in gastroenterology and hepatology, these cross-cutting issues must be actively addressed through ethical design, rigorous validation, and equitable worldwide deployment.

31 August 2022 in Journal of Neurological Surgery Part B: Skull Base
Verified
Journal Article
Closed access
PDF file
KYKaran J. Yagnik
Karan J. Yagnik
DEDana Erickson
Dana Erickson
IBIrina Bancos
Irina Bancos
GCGarret Choby
Garret Choby
NLNadia Laack
Nadia Laack
JGJamie J Van Gompel
Jamie J Van Gompel
Objective Prolactinomas are treated with dopamine agonists (DAs) as first-line therapy and transsphenoidal surgery as an alternative approach for medically failed tumors. We sought to summarize the efficacy of stereotactic radiosurgery (SRS) in the medically and surgically failed prolactinomas as well as in nonsurgical candidates with medically failed prolactinomas by systematic review and meta-analysis. Method A literature search was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guideline. Results A total of 11 articles (total N = 709) met inclusion criteria. Thirty-three percent of patients were able to achieve endocrine remission at a mean follow-up of 54.2 ± 42.2 months with no association between stopping DA and endocrine remission. Sixty-two percent of patients were able to achieve endocrine control with DA therapy and 34% of patients were able to decrease the dose of DA dose when compared with pre-SRS DA dose at the end of the follow-up period. However, 54% of patients required DA at the end of the follow-up to control hyperprolactinemia. Ninety percent of patients were able to achieve radiologic control at the end of the follow-up in comparison to pre-SRS imagings. Furthermore, 26% of patients newly developed hypopituitarism (one or more pituitary hormones) post-SRS throughout the follow-up period. Conclusion This systematic review and meta-analysis demonstrates SRS as an effective adjunct therapy in medically failed nonsurgical candidates or surgically and medically recalcitrant prolactinomas with a 33% chance of achieving endocrine remission, 62% of patients achieved hormonal control with DA and GKRS (gamma knife radio-surgery), with a 34% chance of decreasing DA dose and 90% chance of achieving radiologic control.

5 March 2022 in World Neurosurgery
Verified
Journal Article
Closed access
KYKaran J. Yagnik
Karan J. Yagnik
RNRyan M. Naylor
Ryan M. Naylor
MCMatthew L. Carlson
Matthew L. Carlson
TWTasha L. Welch
Tasha L. Welch
JGJamie J Van Gompel
Jamie J Van Gompel